Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (11-20 of 418) with videos related to

Pageof 42
Sort By:
Pigment Cell & Melanoma Research|September 28, 2023
A twenty year perspective on melanoma therapyKeith T Flaherty
Annals of Internal Medicine|November 3, 2010
Narrative review: BRAF opens the door for therapeutic advances in melanomaKeith T Flaherty
Pigment Cell & Melanoma Research|January 15, 2011
Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research CongressKeith T Flaherty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Is it good or bad to find a BRAF mutation?Keith T Flaherty
Current Opinion in Oncology|April 13, 2004
New molecular targets in melanomaKeith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Sorafenib in renal cell carcinomaKeith T Flaherty
Current Oncology Reports|September 4, 2008
The future of tyrosine kinase inhibitors: single agent or combination?Keith T Flaherty
Annual Review of Medicine|November 1, 2011
Targeting metastatic melanomaKeith T Flaherty
F1000 Medicine Reports|June 10, 2011
Next generation therapies change the landscape in melanomaKeith T Flaherty
Nature Reviews. Clinical Oncology|May 25, 2011
BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas, Keith T Flaherty
Pageof 42

Showing results (11-20 of 418) with videos related to

Sort By:
Pageof 42
Pigment Cell & Melanoma Research|September 28, 2023
A twenty year perspective on melanoma therapyKeith T Flaherty
Annals of Internal Medicine|November 3, 2010
Narrative review: BRAF opens the door for therapeutic advances in melanomaKeith T Flaherty
Pigment Cell & Melanoma Research|January 15, 2011
Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research CongressKeith T Flaherty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Is it good or bad to find a BRAF mutation?Keith T Flaherty
Current Opinion in Oncology|April 13, 2004
New molecular targets in melanomaKeith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Sorafenib in renal cell carcinomaKeith T Flaherty
Current Oncology Reports|September 4, 2008
The future of tyrosine kinase inhibitors: single agent or combination?Keith T Flaherty
Annual Review of Medicine|November 1, 2011
Targeting metastatic melanomaKeith T Flaherty
F1000 Medicine Reports|June 10, 2011
Next generation therapies change the landscape in melanomaKeith T Flaherty
Nature Reviews. Clinical Oncology|May 25, 2011
BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas, Keith T Flaherty
Pageof 42